IOTA is integrated drug
discovery company
based in Cambridge UK.

Our current therapeutic
focus is on glioblastoma
drug research.
PROBLEM
- GLIOBLASTOMA
Standardized approach
Different cancer cells survive in different ways but all patients treated in the same way
Long-term treatment
Most aggressive brain tumour.
Median survival:
15 months
95% mortality
rate within 5 years
50 000 patients die
each year
BENEFITS FOR PHARMA
3-4 days
Time to select drug targets
vs. Months (Big Pharma)
$20-40k
Cost of analysis
vs. $50-100k (Big Pharma)
> 90%
Probability of drug success
vs. 3.9% (Big Pharma)
UNIQUE NETWORK
Based at the heart of Cambridge Biomedical Campus.
LABORATORY
Lab work established with Department of Pharmacology, University of Cambridge
AFFILIATED
Affiliated with the University of Cambridge and the Vrije Universiteit Amsterdam
ESTABLISHED
Established cell biology and computational chemistry platforms
Dr. David Bailey
Co-Founder IOTA Pharmaceuticals
“We have created IOTA specifically to serve researchers in the emerging area of fragment-based drug discovery (FBDD). This field, covering as it does both structure-based drug design, high-content drug screening and structure-guided, property-based lead optimization, is one of the most important and exciting areas in drug discovery today."
Dr. David Bailey
Co-Founder IOTA Pharmaceuticals
“We have created IOTA specifically to serve researchers in the emerging area of fragment-based drug discovery (FBDD). This field, covering as it does both structure-based drug design, high-content drug screening and structure-guided, property-based lead optimization, is one of the most important and exciting areas in drug discovery today."
Contact us:
info@iotapharma.com
IOTA Pharmaceuticals Ltd
St Johns Innovation Centre
Cowley Road
Cambridge
CB4 0WS
Be the first who knows our news!
Once a month you will learn about our latest features and hottest news.